Due to advances on many fronts, from microfluidics to software, flow cytometry is being simplified so that it can be more readily used by a wider range of scientists and clinicians without special ...

[Fremont, CA, USA] – Flow cytometry’s next chapter is here. Opening the door to deeper immunological insights, Cytek Biosciences Inc., a leading provider of flow cytometry instrumentation, announced ...

Selecting Reagents for Multicolor Flow Cytometry (Joe Trotter) Interpreting Flow Cytometry Data (Herzenberg et al) How to do Flow Cytometry Compensation (Mario Roederer) ...

Clinical flow cytometry applications are performed with validated protocols, which have been carefully designed to consider the optimal fluorophore combinations to minimize spectral overlap and for ...

Life science researchers first learned of the utility of flow cytometry as a result of Prof. Wolfgang Göhde’s pioneering work at the University of Münster in the late 1960s and early 1970s. Leonard ...

Flow cytometry’s next chapter is here. Opening the door to deeper immunological insights, Cytek Biosciences Inc., a leading provider of flow cytometry instrumentation, today announced that it has ...

Scientists use multicolor flow cytometry to identify and characterize targeted cellular subpopulations by using multiple fluorescent markers. The technology has seen rapid advancements in recent years ...

Flow cytometry is a powerful technique that allows for examination of multiple proteins within cell populations using fluorescently labeled antibodies. Multi-parameter fluidic-based flow cytometry has ...

The Flow Cytometry shared resource is supported by user fees and the Cancer Center Support Grant, or CCSG. When citing the CCSG, we recommend the following language: This research was supported by the ...

MilliporeSigma’s new ColorWheel flow cytometry portfolio is designed to create antibodies and dyes analogous to a primary conjugated antibody. MilliporeSigma announced the launch of its new ColorWheel ...

Current chemotherapeutic regimens achieve CR in a large percentage of patients with AML. However, relapse after CR remains a significant problem. The presence of leukemic cells at levels too low to be ...